Literature DB >> 1383332

Mapping of epitopes, glycosylation sites, and complement regulatory domains in human decay accelerating factor.

K E Coyne1, S E Hall, S Thompson, M A Arce, T Kinoshita, T Fujita, D J Anstee, W Rosse, D M Lublin.   

Abstract

Decay accelerating factor (DAF, CD55) is a glycophospholipid-anchored membrane protein that protects cells from complement-mediated damage by inhibiting the formation and accelerating the decay of C3/C5 convertases. DAF deletion mutants lacking each of the four short consensus repeats (SCR) or the serine/threonine-rich region (S/T) were created by site-directed mutagenesis. These deletion mutants were expressed by stable transfection in Chinese hamster ovary cells for the purpose of mapping important structural and functional sites in DAF. The epitopes on DAF for 16 murine mAb were mapped by immunoprecipitation studies as follows: SCR1, 6; SCR2, 3; SCR3, 3; SCR4, 3; S/T, 1. Testing of 13 mAb showed complete blocking of DAF function only by 1C6 and 1H4, both directed at SCR3. The single N-linked glycosylation site was confirmed at a location between SCR1 and SCR2, and the multiple O-linked oligosaccharides were localized to the S/T region. Functional activity of DAF mutants was assessed by the ability of these transfected constructs to protect Chinese hamster ovary cells from cytotoxicity induced by rabbit antibody plus human complement. Removal of SCR1 had no effect on DAF function, but individual deletion of SCR2, SCR3, or SCR4 totally abolished DAF function. Surprisingly, deletion of the S/T region totally abrogated DAF function, but this could be restored by a fusion construct placing the four SCR domains of DAF onto the HLA-B44 molecule, implying that the O-glycosylated S/T region serves as an important but nonspecific spacer projecting the DAF functional domains above the plasma membrane. Overall, the creation of DAF deletion mutants has elucidated important structure-function relations in the DAF molecule.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1383332

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  71 in total

1.  Polarized entry of uropathogenic Afa/Dr diffusely adhering Escherichia coli strain IH11128 into human epithelial cells: evidence for alpha5beta1 integrin recognition and subsequent internalization through a pathway involving caveolae and dynamic unstable microtubules.

Authors:  J Guignot; M F Bernet-Camard; C Poüs; L Plançon; C Le Bouguenec; A L Servin
Journal:  Infect Immun       Date:  2001-03       Impact factor: 3.441

2.  Species-specific differences in the organization of the complement-binding protein of orthopoxviruses.

Authors:  S N Shchelkunov; E A Uvarova; A V Totmenin; P F Safronov; L S Sandakhchiev
Journal:  Dokl Biochem Biophys       Date:  2001 Jul-Aug       Impact factor: 0.788

3.  Complement regulation by Kaposi's sarcoma-associated herpesvirus ORF4 protein.

Authors:  O Brad Spiller; Mairi Robinson; Elizabeth O'Donnell; Steven Milligan; B Paul Morgan; Andrew J Davison; David J Blackbourn
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

4.  Specificity of coxsackievirus B3 interaction with human, but not murine, decay-accelerating factor: replacement of a single residue within short consensus repeat 2 prevents virus attachment.

Authors:  Jieyan Pan; Lili Zhang; Lindsey J Organtini; Susan Hafenstein; Jeffrey M Bergelson
Journal:  J Virol       Date:  2014-11-12       Impact factor: 5.103

5.  Role of Src kinases in mobilization of glycosylphosphatidylinositol-anchored decay-accelerating factor by Dr fimbria-positive adhering bacteria.

Authors:  Christophe J Queval; Valérie Nicolas; Isabelle Beau
Journal:  Infect Immun       Date:  2011-04-25       Impact factor: 3.441

6.  Efficient production by sperm-mediated gene transfer of human decay accelerating factor (hDAF) transgenic pigs for xenotransplantation.

Authors:  Marialuisa Lavitrano; Maria Laura Bacci; Monica Forni; Davide Lazzereschi; Carla Di Stefano; Daniela Fioretti; Paola Giancotti; Gabriella Marfé; Loredana Pucci; Luigina Renzi; Hongjun Wang; Antonella Stoppacciaro; Giorgio Stassi; Massimo Sargiacomo; Paola Sinibaldi; Valeria Turchi; Roberto Giovannoni; Giacinto Della Casa; Eraldo Seren; Giancarlo Rossi
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-22       Impact factor: 11.205

7.  Complement regulation at the molecular level: the structure of decay-accelerating factor.

Authors:  P Lukacik; P Roversi; J White; D Esser; G P Smith; J Billington; P A Williams; P M Rudd; M R Wormald; D J Harvey; M D M Crispin; C M Radcliffe; R A Dwek; D J Evans; B P Morgan; R A G Smith; S M Lea
Journal:  Proc Natl Acad Sci U S A       Date:  2004-01-20       Impact factor: 11.205

8.  Complement component 3 interactions with coxsackievirus B3 capsid proteins: innate immunity and the rapid formation of splenic antiviral germinal centers.

Authors:  D R Anderson; C M Carthy; J E Wilson; D Yang; D V Devine; B M McManus
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

9.  Separation of decay-accelerating and cofactor functional activities of Kaposi's sarcoma-associated herpesvirus complement control protein using monoclonal antibodies.

Authors:  Linda Mark; David G Proctor; David J Blackbourn; Anna M Blom; O Brad Spiller
Journal:  Immunology       Date:  2007-08-30       Impact factor: 7.397

10.  Adeno-associated virus mediated delivery of an engineered protein that combines the complement inhibitory properties of CD46, CD55 and CD59.

Authors:  Derek Leaderer; Siobhan M Cashman; Rajendra Kumar-Singh
Journal:  J Gene Med       Date:  2015 Jun-Jul       Impact factor: 4.565

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.